임상화학 분석기 시장 : 제품 유형, 검사 유형별, 최종사용자별, 지역별 - 예측(-2030년)

The global clinical chemistry analyzers market is expected to grow from USD 15.92 billion in 2025 to USD 20.86 billion by 2030, at a CAGR of 5.6% during the forecast period. The market growth is supported by the increasing emphasis on early and accurate disease detection, rising test volumes associated with routine health checkups, and the broader shift toward data-driven clinical decision-making.

Additionally, continuous advancements in analyzer speed, automation, and integration capabilities are enhancing laboratory efficiency and strengthening demand across healthcare settings.

"The reagents segment registered the highest growth rate in the clinical chemistry analyzers market, by product, over the forecast period".

In the clinical chemistry analyzers market, the product segment comprises analyzers, reagents, and other products. The reagents segment is experiencing significant growth, driven by the consistent demand from hospitals & clinics, diagnostic laboratories, and other end users for routine diagnostic testing. Additionally, ongoing usage and the need for regular resupply continue to support the sustained expansion of this segment.

"The basic metabolic panels segment accounted for the largest share in the clinical chemistry analyzers market, by test type, in 2024."

The clinical chemistry analyzers market is segmented by test type into basic metabolic panels, liver function panels, lipid profiles, renal function panels, thyroid function panels, electrolyte panels, and specialty chemical tests. In 2024, the basic metabolic panel segment accounted for the largest share of the market. This can be attributed to the widespread use of these panels for routine health check-ups, monitoring electrolyte and metabolic imbalances, and the early detection of conditions such as diabetes and other lifestyle-related disorders. The emphasis on preventive healthcare and regular patient monitoring further supports the strong demand for basic metabolic panel testing.

"The Asia Pacific is the fastest-growing region in the clinical chemistry analyzers market."

The global clinical chemistry analyzers market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held the largest market share, supported by its well-established healthcare systems, widespread adoption of advanced diagnostic solutions, and robust research and development capabilities. The Asia Pacific region, on the other hand, is expected to achieve the highest CAGR over the forecast period, driven by increasing patient volumes, expanding laboratory networks, and rising demand for early disease detection and preventive healthcare services.

The breakup of the profile of primary participants in the clinical chemistry analyzer market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 28%, D-level - 15%, and Others - 57%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), Hitachi, Ltd. (Japan), EKF Diagnostics Holdings plc (UK), QuidelOrtho Corporation (US), Bruker Corporation (US), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Co., Ltd. (China), DIRUI (China), Teco Diagnostics (US), Balio diagnostics (France), Shenzhen New Industry Biomedical Engineering Co., Ltd. (China) and KPM Analytics (US).

Research Coverage:

This research report categorizes the clinical chemistry analyzers market by product (reagents, analyzers, and other products), by test type (basic metabolic panels, liver panels, lipid profiles, renal profiles, thyroid function panels, electrolyte panels, and specialty chemical tests), by end user (hospitals & clinics, diagnostic laboratories, research laboratories and institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The report's scope encompasses detailed information on the significant factors, including drivers, restraints, opportunities, and challenges, that influence the growth of the clinical chemistry analyzers market. A thorough analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, including partnerships, collaborations, expansions, agreements, new product launches, and recent developments associated with the clinical chemistry analyzers market. This report provides a competitive analysis of upcoming startups in the clinical chemistry analyzer market ecosystem.

Reasons to buy this report:

The report will assist market leaders/new entrants in this market by providing information on the closest approximations of the revenue numbers for the overall clinical chemistry analyzer market and its subsegments. This report will help stakeholders understand the competitive landscape and gain valuable insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising geriatric population and increasing prevalence of chronic & lifestyle diseases, growing adoption of point-of-care testing devices, spiking demand for laboratory automation), opportunities (increasing government initiatives and funding for preventive care, growth opportunities in emerging economies), restraints (requirement for high capital investments and shortage of skilled laboratory technicians, availability of refurbished analyzers), and challenges (increasing regulatory requirements, high degree of consolidation) influencing the growth of the clinical chemistry analyzers market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the clinical chemistry analyzers market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the clinical chemistry analyzers market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the clinical chemistry analyzers market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), and Siemens Healthineers AG (Germany), among others, in the clinical chemistry analyzers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 TRENDS/DISRUPTIONS IMPACTING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CLINICAL CHEMISTRY ANALYZERS MARKET OVERVIEW
• 3.2 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT, 2026 VS. 2031 (USD MILLION)
• 3.3 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE, 2026 VS. 2031 (USD MILLION)
• 3.4 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE, 2026 VS. 2031 (USD MILLION)
• 3.5 CLINICAL CHEMISTRY ANALYZERS MARKET, BY SAMPLE TYPE, 2026 VS. 2031 (USD MILLION)
• 3.6 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER, 2026 VS. 2031 (USD MILLION)
• 3.7 CLINICAL CHEMISTRY ANALYZERS MARKET: REGIONAL GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising geriatric population and increasing prevalence of chronic & lifestyle diseases
    • 4.2.1.2 Growing adoption of point-of-care testing devices
    • 4.2.1.3 Increasing demand for laboratory automation
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Requirement for high capital investments and shortage of skilled laboratory technicians
    • 4.2.2.2 Availability of refurbished analyzers
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing government initiatives and funding for preventive care
    • 4.2.3.2 Growth potential of emerging markets
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Increasing regulatory requirements
    • 4.2.4.2 High degree of consolidation
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS
  • 4.3.2 WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
  • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 ROLE IN ECOSYSTEM
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY PRODUCT, 2024-2026
  • 5.6.2 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS, BY KEY PLAYER, 2024-2026
  • 5.6.3 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS PRODUCTS, BY REGION, 2024-2026
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 382200
  • 5.7.2 EXPORT SCENARIO FOR HS CODE 382200
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: INTEGRATED CHEMISTRY & IMMUNOASSAY ANALYZER TO IMPROVE LAB EFFICIENCY
  • 5.11.2 CASE STUDY 2: CORE LAB AUTOMATION TO OPTIMIZE MULTI-DISCIPLINE TESTING
  • 5.11.3 CASE STUDY 3: AUTOMATED WORKFLOW TO DRIVE OPERATIONAL GAINS IN MULTI-HOSPITAL LAB
• 5.12 IMPACT OF 2025 US TARIFF ON CLINICAL CHEMISTRY ANALYZERS MARKET
  • 5.12.1 KEY TARIFF RATES
  • 5.12.2 PRICE IMPACT ANALYSIS
  • 5.12.3 KEY IMPACT ON COUNTRY/REGION
    • 5.12.3.1 North America
    • 5.12.3.2 Europe
    • 5.12.3.3 Asia Pacific
  • 5.12.4 IMPACT ON END-USE INDUSTRIES
    • 5.12.4.1 Hospitals
    • 5.12.4.2 Clinical laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 AUTOMATION AND HIGH-THROUGHPUT ANALYZER PLATFORMS
  • 6.1.2 ADVANCED OPTICAL AND DETECTION TECHNOLOGIES
  • 6.1.3 INTEGRATED REAGENT AND CONSUMABLE TECHNOLOGIES
  • 6.1.4 INTELLIGENT SOFTWARE AND DATA MANAGEMENT SYSTEMS
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 PRE-ANALYTICAL SYSTEMS
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3.1 SHORT TERM (2025-2027) | PROCESS IMPROVEMENT & STANDARDIZATION
    • 6.3.1.1 Focus areas:
      • 6.3.1.1.1 Analyzer hardware optimization
      • 6.3.1.1.2 Product innovations
      • 6.3.1.1.3 Market adoption
  • 6.3.2 MID TERM (2027-2030) | MATERIAL DIVERSIFICATION & SUSTAINABILITY
    • 6.3.2.1 Focus areas:
      • 6.3.2.1.1 Analyzer hardware optimization
      • 6.3.2.1.2 Product innovations
      • 6.3.2.1.3 Market adoption
  • 6.3.3 LONG TERM (2030-2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT
    • 6.3.3.1 Focus areas:
      • 6.3.3.1.1 Analyzer hardware optimization
      • 6.3.3.1.2 Product innovations
      • 6.3.3.1.3 Market adoption
• 6.4 PATENT ANALYSIS
  • 6.4.1 LIST OF MAJOR PATENTS
• 6.5 FUTURE APPLICATIONS
• 6.6 IMPACT OF AI/GEN AI ON CLINICAL CHEMISTRY ANALYZERS MARKET
  • 6.6.1 INTRODUCTION
  • 6.6.2 TOP USE CASES & MARKET POTENTIAL
  • 6.6.3 AI USE CASES
  • 6.6.4 IMPLEMENTATION OF AI USE CASES, BY COMPANY
  • 6.6.5 FUTURE OF AI

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CLINICAL CHEMISTRY ANALYZERS MARKET
    • 7.2.1.1 Eco-friendly initiatives
• 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 REAGENTS
  • 9.2.1 RECURRENT PURCHASE REQUIREMENT OF REAGENTS TO DRIVE MARKET
• 9.3 ANALYZERS
  • 9.3.1 SEMI-AUTOMATIC ANALYZERS
    • 9.3.1.1 Cost-effectiveness to propel segment growth
  • 9.3.2 FULLY AUTOMATIC ANALYZERS
    • 9.3.2.1 Rapid sample processing and reduction of turnaround times to boost market growth
  • 9.3.3 POINT-OF-CARE ANALYZERS
    • 9.3.3.1 Increasing adoption of PoC technologies to drive segment growth
• 9.4 OTHER PRODUCTS

10 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE

• 10.1 INTRODUCTION
• 10.2 BASIC METABOLIC PANEL
  • 10.2.1 RISING INCIDENCE OF DIABETES AND CHRONIC KIDNEY DISEASES TO DRIVE MARKET
• 10.3 LIVER PANEL
  • 10.3.1 INCREASE IN LIVER-RELATED DISEASES TO AID MARKET GROWTH
• 10.4 RENAL PROFILE
  • 10.4.1 GROWING PREVALENCE OF CHRONIC KIDNEY DISEASES TO BOOST INCREASED RENAL PROFILE TESTING
• 10.5 LIPID PROFILE
  • 10.5.1 RAPID RISE IN OBESITY RATES TO PROPEL MARKET GROWTH
• 10.6 THYROID FUNCTION PANEL
  • 10.6.1 GROWING PREVENTIVE SCREENING AND AWARENESS TO SUPPORT THYROID FUNCTION PANEL TESTING
• 10.7 ELECTROLYTE PANEL
  • 10.7.1 INCREASING PREVALENCE OF HYPERTENSION AND KIDNEY DISEASES TO FUEL MARKET GROWTH
• 10.8 SPECIALTY CHEMICAL TESTS
  • 10.8.1 TARGETED CLINICAL APPLICATIONS TO BOOST DEMAND FOR SPECIALTY CHEMICAL TESTS

11 CLINICAL CHEMISTRY ANALYZERS MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 LABORATORY TESTS
  • 11.2.1 INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE MARKET GROWTH
• 11.3 POINT-OF-CARE TESTS
  • 11.3.1 RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO FAVOR MARKET GROWTH

12 CLINICAL CHEMISTRY ANALYZERS MARKET, BY SAMPLE TYPE

• 12.1 INTRODUCTION
• 12.2 BLOOD, SERUM, AND PLASMA
  • 12.2.1 EXPANDING DIAGNOSTIC NEEDS TO ACCELERATE GROWTH OF BLOOD, SERUM, AND PLASMA TESTING
• 12.3 URINE
  • 12.3.1 GROWING RENAL DISEASE BURDEN AND PREVENTIVE SCREENING NEEDS TO FOCUS ON URINE-BASED CLINICAL CHEMISTRY TESTING
• 12.4 OTHER SAMPLE TYPES

13 CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 HOSPITALS & CLINICS
  • 13.2.1 EXPANSION OF HOSPITAL INFRASTRUCTURE AND HEALTHCARE INVESTMENTS TO PROPEL DEMAND
• 13.3 DIAGNOSTIC LABORATORIES
  • 13.3.1 FOCUS ON COST-EFFECTIVENESS TO INCREASE OUTSOURCING ACTIVITIES TO DIAGNOSTIC LABORATORIES
• 13.4 RESEARCH LABORATORIES & INSTITUTES
  • 13.4.1 GROWTH IN FUNDING FOR LIFE SCIENCE RESEARCH TO BOOST MARKET GROWTH
• 13.5 OTHER END USERS

14 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 US to dominate North American clinical chemistry analyzers market during study period
  • 14.2.2 CANADA
    • 14.2.2.1 Spike in prevalence of chronic and lifestyle diseases to drive market
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Increasing healthcare expenditure to propel market growth
  • 14.3.2 UK
    • 14.3.2.1 Growing number of accredited diagnostic and hospital laboratories to augment market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Increasing demand for early disease diagnosis to augment market growth
  • 14.3.4 ITALY
    • 14.3.4.1 Prevalence of age-related chronic conditions among geriatric population to spur market growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Increasing prevalence of age-associated disorders to drive market growth
  • 14.3.6 RUSSIA
    • 14.3.6.1 Increasing access to quality healthcare to support market growth
  • 14.3.7 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Increasing awareness of preventive care to drive demand for clinical chemistry analyzers
  • 14.4.2 JAPAN
    • 14.4.2.1 Well-developed healthcare system and availability of universal reimbursement policies to drive market
  • 14.4.3 INDIA
    • 14.4.3.1 Increasing private and public investments with rising prevalence of diseases to propel market growth
  • 14.4.4 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Universal healthcare access to drive adoption of clinical chemistry analyzers
  • 14.5.2 MEXICO
    • 14.5.2.1 Rising chronic conditions and healthcare modernization to accelerate diagnostic adoption
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 KINGDOM OF SAUDI ARABIA
    • 14.6.1.1 Increasing healthcare expenditure to boost market growth
  • 14.6.2 UAE
    • 14.6.2.1 Improvements in healthcare infrastructure to support market growth
  • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CLINICAL CHEMISTRY ANALYZERS MARKET
• 15.3 REVENUE ANALYSIS, 2021-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 15.4.2 US MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product footprint
    • 15.5.5.4 Analyzers footprint
    • 15.5.5.5 Sample type footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 15.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT LAUNCHES & APPROVALS
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 ABBOTT LABORATORIES
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Deals
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Product launches
      • 16.1.2.3.2 Deals
      • 16.1.2.3.3 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 SIEMENS HEALTHINEERS AG
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches and approvals
      • 16.1.3.3.2 Deals
      • 16.1.3.3.3 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 DANAHER CORPORATION
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product launches and approvals
      • 16.1.4.3.2 Expansions
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 THERMO FISHER SCIENTIFIC INC.
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 HORIBA GROUP
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches and approvals
  • 16.1.7 SYSMEX CORPORATION
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Deals
      • 16.1.7.3.2 Expansions
  • 16.1.8 QUIDELORTHO CORPORATION
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Deals
      • 16.1.8.3.2 Expansions
  • 16.1.9 HITACHI LTD.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
  • 16.1.10 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product launches
      • 16.1.10.3.2 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 RANDOX LABORATORIES LTD.
  • 16.2.2 VITALSCIENTIFIC
  • 16.2.3 MEDICA CORPORATION
  • 16.2.4 BIOBASE GROUP
  • 16.2.5 GENRUI BIOTECH INC.
  • 16.2.6 SFRI
  • 16.2.7 TRIVITRON HEALTHCARE
  • 16.2.8 MERIL
  • 16.2.9 ERBA GROUP
  • 16.2.10 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
  • 16.2.11 TECO DIAGNOSTICS
  • 16.2.12 DIRUI
  • 16.2.13 BALIO DIAGNOSTICS
  • 16.2.14 SHENZHEN NEW INDUSTRY BIOMEDICAL ENGINEERING CO., LTD.
  • 16.2.15 KPM ANALYTICS

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
• 17.2 RESEARCH APPROACH
  • 17.2.1 SECONDARY DATA
    • 17.2.1.1 Key secondary sources
    • 17.2.1.2 Key data from secondary sources
  • 17.2.2 PRIMARY DATA
    • 17.2.2.1 Key primary sources
    • 17.2.2.2 Key objectives of primary research
    • 17.2.2.3 Key data from primary sources
    • 17.2.2.4 Key industry insights
    • 17.2.2.5 Breakdown of primary interviews
• 17.3 MARKET SIZE ESTIMATION
  • 17.3.1 BOTTOM-UP APPROACH
    • 17.3.1.1 Company revenue estimation approach
    • 17.3.1.2 Presentations of companies and primary interviews
    • 17.3.1.3 Growth forecast
    • 17.3.1.4 CAGR projections
  • 17.3.2 TOP-DOWN APPROACH
• 17.4 DATA TRIANGULATION
• 17.5 MARKET SHARE ASSESSMENT
• 17.6 STUDY ASSUMPTIONS
  • 17.6.1 PARAMETRIC ASSUMPTIONS
• 17.7 RESEARCH LIMITATIONS
• 17.8 RISK ASSESSMENT

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS. SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS